|
|
|
The value of epigenetic markers in esophageal
cancer |
| Xiao-Mei ZHANG,Ming-Zhou GUO, |
| Department of Gastroenterology
& Hepatology, Chinese PLA General Hospital, Beijing 100853, China; |
|
|
|
|
Abstract Developing esophageal cancer is a multi-step process that begins with the accumulation of genetic and epigenetic alterations, and leads to the activation of oncogenes and the inactivation or loss of tumor suppressor genes (TSG). In addition to genetic alteration, epigenetic modifications, and in particular DNA methylation, are recognized as a common molecular alteration in human tumors. In esophageal cancer, aberrant methylation of promoter regions occurs not only in advanced cancer, but also in premalignant lesions. DNA methylation is related to survival time and sensitivity of chemoradiotherapy. This review is mainly focused on epigenetic changes in esophageal cancer and the value of early detection for patient prognosis, treatment choices, and potential targeting therapy.
|
| Keywords
epigenetics
DNA methylation
esophageal cancer
dysplasia
|
|
Issue Date: 05 December 2010
|
|
|
Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin, 2005, 55(2): 74―108
PMID: 15761078
|
|
Hu N, Dawsey S M, Wu M, Bonney G E, He L J, Han X Y, Fu M, Taylor P R. Family history of oesophageal cancer in Shanxi Province. Int J Epidemiol, 1992, 21(5): 877―822
PMID: 1468848
|
|
Yang C S. Research on esophageal cancer in China: a review.Cancer Res, 1980, 40(8 Pt 1): 2633―2644
PMID: 6992989
|
|
Taylor P R, Dawsey S M, Hu N, Albanes D, Wu M. Nutritional interventionto prevent hereditary cancer.J Natl CancerInst Monogr, 1995, (17): 43―47
PMID: 8573452
|
|
Carter C L, Hu N, Wu M, Lin P Z, Murigande C, Bonney G E. Segregation analysis of esophageal cancer in 221 high-risk Chinesefamilies.J Natl Cancer Inst, 1992, 84(10): 771―776
PMID: 1573663
|
|
Mu?oz N. Epidemiological aspects of oesophageal cancer.Endoscopy, 1993, 25(9): 609―612
PMID: 8119215
|
|
Nielsen N H, Mikkelsen F, Hansen J P. Oesophageal cancer in Greenland:selected epidemiological and clinical aspects.J Cancer Res Clin Oncol, 1979, 94(1): 69―80
PMID: 381317
|
|
Cameron A J. Epidemiology of columnar-lined esophagus and adenocarcinoma.Gastroenterol Clin North Am, 1997, 26(3): 487―494
PMID: 9309399
|
|
Okano J, Snyder L, Rustgi A K. Genetic alterations in esophageal cancer.Methods Mol Biol, 2003, 222: 131―145
PMID: 12710684
|
|
Vogelstein B, Kinzler K W. The multistep nature of cancer.TrendsGenet, 1993, 9(4): 138―141
PMID: 8516849
|
|
Zhang W, Gl?ckner S C, Guo M, Machida E O, Wang D H, Easwaran H, Van Neste L, Herman J G, Schuebel K E, Watkins D N, Ahuja N, Baylin S B. Epigenetic inactivation of the canonical Wnt antagonistSRY-box containing gene 17 in colorectal cancer.Cancer Res, 2008, 68(8): 2764―2772
PMID: 18413743
|
|
Wang J S, Guo M, Montgomery E A, Thompson R E, Cosby H, Hicks L, Wang S, Herman J G, Canto M I. DNA promoter hypermethylation of p16 and APC predictsneoplastic progression in Barrett's esophagus.Am J Gastroenterol, 2009, 104(9): 2153―2160
PMID: 19584833
|
|
Carmona F J, Esteller M. Epigenomics of human colon cancer. MutatRes, 2010, 693(1―2):53―60
PMID: 20691710
|
|
Mokrowiecka A, Wierzchniewska-?awska A, Smolarz B, Romanowicz-Makowska H, Malecka-Panas E. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence]. Pol Merkur Lekarski, 2009, 26(155): 385―389
PMID: 19606680
|
|
Kohler E M, Brauburger K, Behrens J, Schneikert J. Contribution of the 15 amino acid repeats of truncatedAPC to beta-catenin degradation and selection of APC mutations incolorectal tumours from FAP patients.Oncogene, 2010, 29(11): 1663―1671
PMID: 19966865
|
|
Holliday R. The inheritance of epigenetic defects.Science, 1987, 238(4824): 163―170
PMID: 3310230
|
|
Jones P A, Baylin S B. The fundamentalrole of epigenetic events in cancer.NatRev Genet, 2002, 3(6): 415―428
PMID: 12042769
|
|
Riggs A D, Pfeifer G P. X-chromosome inactivation and cell memory.Trends Genet, 1992, 8(5): 169―174
PMID: 1369742
|
|
Ali A B, Iau P T, Sng J H. Cancer-specific methylation in the BRCA1promoter in sporadic breast tumours. MedOncol, 2010Feb5. DOI: 10.1007/S12032-010-9438-Y
doi: 10.1007/S12032-010-9438-Y
|
|
Merlo A, Herman J G, Mao L, Lee D J, Gabrielson E, Burger P C, Baylin S B, Sidransky D. 5′ CpG island methylation is associatedwith transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1in human cancers.Nat Med, 1995, 1(7): 686―692
PMID: 7585152
|
|
Guo M, House M G, Suzuki H, Ye Y, Brock M V, Lu F, Liu Z, Rustgi A K, Herman J G. Epigenetic silencing of CDX2 is a feature of squamous esophagealcancer.Int J Cancer, 2007, 121(6): 1219―1226
PMID: 17534889
|
|
Guo M, House M G, Akiyama Y, Qi Y, Capagna D, Harmon J, Baylin S B, Brock M V, Herman J G. Hypermethylation of the GATA gene family in esophageal cancer.Int J Cancer, 2006, 119(9): 2078―2083
PMID: 16823849
|
|
Aguilera O, Fraga M F, Ballestar E, Paz M F, Herranz M, Espada J, García J M, Mu?oz A, Esteller M, González-Sancho J M. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1)gene in human colorectal cancer.Oncogene, 2006, 25(29): 4116―4121
PMID: 16491118
|
|
Martinez R, Setien F, Voelter C, Casado S, Quesada M P, Schackert G, Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8is a common hallmark of relapsed glioblastoma multiforme.Carcinogenesis, 2007, 28(6): 1264―1268
PMID: 17272309
|
|
Blanco D, Vicent S, Fraga M F, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga L M. Molecular analysis of a multisteplung cancer model induced by chronic inflammation reveals epigeneticregulation of p16 and activation of the DNA damage response pathway.Neoplasia, 2007, 9(10): 840―852
PMID: 17971904
|
|
Yue W, Sun Q, Dacic S, Landreneau R J, Siegfried J M, Yu J, Zhang L. Downregulationof Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer.Carcinogenesis, 2008, 29(1): 84―92
PMID: 18048388
|
|
Lee B B, Lee E J, Jung E H, Chun H K, Chang D K, Song S Y, Park J, Kim D H. Aberrant methylation of APC, MGMT, RASSF2A,and Wif-1 genes in plasma as a biomarker for early detection of colorectalcancer.Clin Cancer Res, 2009, 15(19): 6185―6191
PMID: 19773381
|
|
Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grützmann R, Pilarsky C, Sledziewski A. DNA methylation biomarkers for blood-based colorectalcancer screening.Clin Chem, 2008, 54(2): 414―423
PMID: 18089654
|
|
Atherfold P A, Jankowski J A. Molecular biology of Barrett's cancer.Best Pract Res Clin Gastroenterol, 2006, 20(5): 813―827
PMID: 16997163
|
|
Dulai G S, Guha S, Kahn K L, Gornbein J, Weinstein W M. Preoperative prevalence ofBarrett's esophagus in esophageal adenocarcinoma: a systematicreview.Gastroenterology, 2002, 122(1): 26―33
PMID: 11781277
|
|
Corley D A, Levin T R, Habel L A, Weiss N S, Buffler P A. Surveillance and survivalin Barrett's adenocarcinomas: a population-based study.Gastroenterology, 2002, 122(3): 633―640
PMID: 11874995
|
|
McManus D T, Olaru A, Meltzer S J. Biomarkers of esophageal adenocarcinomaand Barrett's esophagus.Cancer Res, 2004, 64(5): 1561―1569
PMID: 14996709
|
|
Bian Y S, Osterheld M C, Fontolliet C, Bosman F T, Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs earlyduring neoplastic progression in Barrett's esophagus.Gastroenterology, 2002, 122(4): 1113―1121
PMID: 11910361
|
|
Wong D J, Paulson T G, Prevo L J, Galipeau P C, Longton G, Blount P L, Reid B J. p16(INK4a) lesions are common, early abnormalities thatundergo clonal expansion in Barrett's metaplastic epithelium.Cancer Res, 2001, 61(22): 8284―8289
PMID: 11719461
|
|
Klump B, Hsieh C J, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16promoter during neoplastic progression in Barrett's esophagus.Gastroenterology, 1998, 115(6): 1381―1386
PMID: 9834265
|
|
Wong D J, Barrett M T, St?ger R, Emond M J, Reid B J. p16INK4apromoter is hypermethylated at a high frequency in esophageal adenocarcinomas.Cancer Res, 1997, 57(13): 2619―2622
PMID: 9205067
|
|
Eads C A, Lord R V, Wickramasinghe K, Long T I, Kurumboor S K, Bernstein L, Peters J H, DeMeester S R, DeMeester T R, Skinner K A, Laird P W. Epigeneticpatterns in the progression of esophageal adenocarcinoma.Cancer Res, 2001, 61(8): 3410―3418
PMID: 11309301
|
|
Guo M, Ren J, House M G, Qi Y, Brock M V, Herman J G. Accumulation of promoter methylation suggests epigeneticprogression in squamous cell carcinoma of the esophagus.Clin Cancer Res, 2006, 12(15): 4515―4522
PMID: 16899597
|
|
Guo M, Ren J, Brock M V, Herman J G, Carraway H E. Promoter methylation of HIN-1in the progression to esophageal squamous cancer.Epigenetics, 2008, 3(6): 336―341
PMID: 19098448
|
|
Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton J P, David S, Agarwal R, Selaru F M, Sato F, Abraham J M, Beer D G, Mori Y, Shimada Y, Meltzer S J. Promoter hypermethylationof CDH13 is a common, early event in human esophageal adenocarcinogenesisand correlates with clinical risk factors.Int J Cancer, 2008, 123(10): 2331―2336
PMID: 18729198
|
|
Jin Z, Hamilton J P, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer D G, Agarwal R, Abraham J M, Meltzer S J. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associatedesophageal neoplastic progression.CancerEpidemiol Biomarkers Prev, 2008, 17(1): 111―117
PMID: 18199717
|
|
Jin Z, Mori Y, Hamilton J P, Olaru A, Sato F, Yang J, Ito T, Kan T, Agarwal R, Meltzer S J. Hypermethylation of the somatostatin promoter is a common, earlyevent in human esophageal carcinogenesis.Cancer, 2008, 112(1): 43―49
PMID: 17999418
|
|
Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton J P, Ito T, Wang S, David S, Agarwal R, Beer D G, Abraham J M, Meltzer S J. Hypermethylation of tachykinin-1 is a potential biomarker in humanesophageal cancer.Clin Cancer Res, 2007, 13(21): 6293―6300
PMID: 17975140
|
|
Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton J P, Kan T, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Hypermethylation of the nel-like1 gene is a common and early event and is associated with poor prognosisin early-stage esophageal adenocarcinoma.Oncogene, 2007, 26(43): 6332―6340
PMID: 17452981
|
|
Kuester D, Dar A A, Moskaluk C C, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, El-Rifai W, Schneider-Stock R. Early involvement of death-associatedprotein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association withclinical progression.Neoplasia, 2007, 9(3): 236―245
PMID: 17401463
|
|
Hamilton J P, Sato F, Jin Z, Greenwald B D, Ito T, Mori Y, Paun B C, Kan T, Cheng Y, Wang S, Yang J, Abraham J M, Meltzer S J. Reprimo methylation is apotential biomarker of Barrett's-Associated esophageal neoplasticprogression.Clin Cancer Res, 2006, 12(22): 6637―6642
PMID: 17121882
|
|
Anupam K, Tusharkant C, Gupta S D, Ranju R. Loss of disabled-2 expression is an early event in esophagealsquamous tumorigenesis.World J Gastroenterol, 2006, 12(37): 6041―6045
PMID: 17009406
|
|
Clément G, Braunschweig R, Pasquier N, Bosman F T, Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.J Pathol, 2006, 208(1): 100―107
PMID: 16278815
|
|
Zou H, Osborn N K, Harrington J J, Klatt K K, Molina J R, Burgart L J, Ahlquist D A. Frequent methylation of eyes absent 4 gene in Barrett's esophagusand esophageal adenocarcinoma.Cancer EpidemiolBiomarkers Prev, 2005, 14(4): 830―834
PMID: 15824152
|
|
Campbell N P, Villaflor V M. Neoadjuvant treatment of esophageal cancer.World J Gastroenterol, 2010, 16(30): 3793―3803
PMID: 20698042
|
|
Hyngstrom J R, Posner M C. Neoadjuvantstrategies for the treatment of locally advanced esophageal cancer.J Surg Oncol, 2010, 101(4): 299―304
PMID: 20187065
|
|
Kim M P, Correa A M, Lee J, Rice D C, Roth J A, Mehran R J, Walsh G L, Ajani J A, Maru D M, Chang J Y, Marom E M, Macapinlac H A, Lee J H, Vaporciyan A A, Rice T, Swisher S G, Hofstetter W L. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery:an orphan status.Ann Thorac Surg, 2010, 90(3): 884―890, discussion 890―891
PMID: 20732513
|
|
Metzger R, Heukamp L, Drebber U, Bollschweiler E, Zander T, Hoelscher A H, Warnecke-Eberz U. CUL2 and STK11 as novel response-predictivegenes for neoadjuvant radiochemotherapy in esophageal cancer.Pharmacogenomics, 2010, 11(8): 1105―1113
PMID: 20712528
|
|
Esteller M, Garcia-Foncillas J, Andion E, Goodman S N, Hidalgo O F, Vanaclocha V, Baylin S B, Herman J G. Inactivationof the DNA-repair gene MGMT and the clinical response of gliomas toalkylating agents.N Engl J Med, 2000, 343(19): 1350―1354
PMID: 11070098
|
|
Rivera A L, Pelloski C E, Gilbert M R, Colman H, De La Cruz C, Sulman E P, Bekele B N, Aldape K D. MGMT promotermethylation is predictive of response to radiotherapy and prognosticin the absence of adjuvant alkylating chemotherapy for glioblastoma.Neuro Oncol, 2010, 12(2): 116―121
PMID: 20150378
|
|
Hamilton J P, Sato F, Jin Z, Greenwald B D, Ito T, Mori Y, Paun B C, Kan T, Cheng Y, Wang S, Yang J, Abraham J M, Meltzer S J. Reprimo methylation is apotential biomarker of Barrett's-Associated esophageal neoplasticprogression.Clin Cancer Res, 2006, 12(22): 6637―6642
PMID: 17121882
|
|
Hamilton J P, Sato F, Greenwald B D, Suntharalingam M, Krasna M J, Edelman M J, Doyle A, Berki A T, Abraham J M, Mori Y, Kan T, Mantzur C, Paun B, Wang S, Ito T, Jin Z, Meltzer S J. Promoter methylation and response to chemotherapy andradiation in esophageal cancer.Clin GastroenterolHepatol, 2006, 4(6): 701―708
PMID: 16678495
|
|
Mandelker D L, Yamashita K, Tokumaru Y, Mimori K, Howard D L, Tanaka Y, Carvalho A L, Jiang W W, Park H L, Kim M S, Osada M, Mori M, Sidransky D. PGP9.5 promoter methylationis an independent prognostic factor for esophageal squamous cell carcinoma.Cancer Res, 2005, 65(11): 4963―4968
PMID: 15930319
|
|
Li L W, Yu X Y, Yang Y, Zhang C P, Guo L P, Lu S H. Expression of esophageal cancer related gene 4 (ECRG4),a novel tumor suppressor gene, in esophageal cancer and its inhibitoryeffect on the tumor growth in vitro and in vivo.Int J Cancer, 2009, 125(7): 1505―1513
PMID: 19521989
|
|
Brock M V, Gou M, Akiyama Y, Muller A, Wu T T, Montgomery E, Deasel M, Germonpré P, Rubinson L, Heitmiller R F, Yang S C, Forastiere A A, Baylin S B, Herman J G. Prognostic importance of promoter hypermethylationof multiple genes in esophageal adenocarcinoma.Clin Cancer Res, 2003, 9(8): 2912―2919
PMID: 12912936
|
|
Kawakami K, Brabender J, Lord R V, Groshen S, Greenwald B D, Krasna M J, Yin J, Fleisher A S, Abraham J M, Beer D G, Sidransky D, Huss H T, Demeester T R, Eads C, Laird P W, Ilson D H, Kelsen D P, Harpole D, Moore M B, Danenberg K D, Danenberg P V, Meltzer S J. Hypermethylated APC DNA in plasma and prognosis of patients withesophageal adenocarcinoma.J Natl CancerInst, 2000, 92(22): 1805―1811
PMID: 11078757
|
|
Lee E J, Lee B B, Kim J W, Shim Y M, Hoseok I, Han J, Cho E Y, Park J, Kim D H. Aberrant methylation of Fragile Histidine Triad gene is associatedwith poor prognosis in early stage esophageal squamous cell carcinoma.Eur J Cancer, 2006, 42(7): 972―980
PMID: 16564166
|
|
Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton J P, Kan T, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Hypermethylation of the nel-like1 gene is a common and early event and is associated with poor prognosisin early-stage esophageal adenocarcinoma. Oncogene, 2007, 26(43): 6332―6340
|
|
Ohta M, Mimori K, Fukuyoshi Y, Kita Y, Motoyama K, Yamashita K, Ishii H, Inoue H, Mori M, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Clinical significance ofthe reduced expression of G protein gamma 7 (GNG7) in oesophagealcancer.Br J Cancer, 2008, 98(2): 410―417
PMID: 18219292
|
|
Lee E J, Lee B B, Han J, Cho E Y, Shim Y M, Park J, Kim D H. CpG islandhypermethylation of E-cadherin (CDH1) and integrin alpha4 is associatedwith recurrence of early stage esophageal squamous cell carcinoma.Int J Cancer, 2008, 123(9): 2073―2079
PMID: 18697202
|
|
Zare M, Jazii F R, Alivand M R, Nasseri N K, Malekzadeh R, Yazdanbod M. Qualitative analysis of Adenomatous Polyposis Coli promoter:hypermethylation, engagement and effects on survival of patients withesophageal cancer in a high risk region of the world, a potentialmolecular marker.BMC Cancer, 2009, 9: 24
PMID: 19149902
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
